A phase 1, first in man, study to assess the safety, pharmacokinetic profile and antiretroviral efficacy of C34-PEG-4-Chol, a novel peptide fusion inhibitor for the treatment of HIV-infection

Trial Profile

A phase 1, first in man, study to assess the safety, pharmacokinetic profile and antiretroviral efficacy of C34-PEG-4-Chol, a novel peptide fusion inhibitor for the treatment of HIV-infection

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs C34-PEG-4-Chol (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 02 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 11 Feb 2016 Planned End Date changed to 8 Dec 2015 as reported by United Kingdom Clinical Research Network.
    • 15 Oct 2015 Accrual to date is 35% according to United Kingdom Clinical Research Network record record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top